Clinuvel Pharmaceuticals (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) has been granted a trading halt by the ASX this morning, with its shares placed in pre-open.
Clinuvel requested the halt pending capital raising details.
The company recently revealed that a Phase II study of its drug implant SCENESSE® in Singapore has received the necessary regulatory and ethics committee approvals and commenced recruitment.
Sixty adults with vitiligo, a skin pigmentation disorder, will be recruited to the seven month, double-blind, placebo controlled study at the National Skin Centre, the leading dermatology hospital in Singapore.
The halt will remain in place until the opening of trade on Wednesday 14th May 2014, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.